Background: The Surveillance, Epidemiology and End Results (SEER)-Medicare data combine clinical information from population-based cancer registries with Medicare claims. These data have been used in many studies to understand cancer screening, treatment, outcomes, and costs. However, until recently, these data included limited information related to the characteristics and outcomes of cancer patients residing in or admitted to nursing homes.
N ursing homes provide many services to cancer patients ranging from postacute skilled care following a hospitalization, to long-term custodial services, to end-of-life care. 1, 2 Much of the understanding we have about cancer patients who receive care in nursing homes is based on studies of palliative and terminal care. [3] [4] [5] Less is understood about the variation among the population of cancer patients in nursing homes, particularly among those who receive postacute skilled nursing, rehabilitation, and symptom management. Cancer patients who are discharged from an inpatient hospital to receive postacute care in skilled nursing facilities receive assistance in everything from performing activities of daily living such as eating, bathing, and dressing, to handling medication and monitoring vital signs. Postacute care delivered to cancer patients can also include skilled services such as physical and occupational therapy, restorative nursing, and hospice care. Depending on the patient's condition, care can be temporary, such as recovery from cancer-directed surgery, or long-term, continuing the rest of a patient's life.
Much of what we know about cancer screening, treatment, and costs for Medicare beneficiaries comes from the linked Surveillance, Epidemiology and End Results (SEER) registry and Medicare data. 6 The SEER-Medicare data result from linking patients newly diagnosed with cancer in population-based cancer registries to their Medicare enrollment and claims files. Although the SEER-Medicare data are a valuable resource for cancer health services research, these data have limited information about the characteristics and outcomes of cancer patients receiving care in the United States' almost 16,000 nursing homes. The SEER registries collect no information about care in the nursing home and Medicare claims from nursing homes are limited to short-term postacute care claims for fee-for-service (FFS) patients. Therefore, the growing population of Medicare Advantage (MA) enrollees, currently representing ∼1/3 of Medicare beneficiaries, 7 are excluded as claims data are not available.
In addition, the care of Medicare beneficiaries receiving longterm custodial services is not reimbursed by Medicare and thus not included in Medicare data. To enhance information about nursing home residents with cancer, the National Cancer Institute has recently linked the SEER-Medicare files with the Minimum Data Set (MDS), a resident assessment instrument that is completed for all nursing home residents upon admission and following at regular intervals. This expanded data resource enables researchers to ask new questions as they relate to the types of cancer patients in nursing homes, the delivery of nursing home care to cancer patients, and cancer patients' outcomes.
NEW CONTRIBUTION
The objective of this paper is to provide an overview of the new SEER-Medicare-MDS dataset in an effort to promote research to better understand the characteristics, outcomes, and quality of care for cancer patients who receive postacute, hospice, or long-term care in nursing homes. The overview includes a description of the linkage of the SEER-Medicare data to the MDS and characteristics of cancer patients receiving care in a nursing home. We also discuss the potential uses of this new data resource for cancer health services research.
METHODS

Data Sources
SEER-Medicare
The SEER data are obtained from population-based cancer registries that are funded by the National Cancer Institute. The SEER registries collect clinical information about all incident cancers occurring in patients living within defined geographic areas, representing ∼30% of the United States population. 8 For each patient, the SEER data include demographic information such as age, sex, and race; the number of primary incident cancers; month and year of diagnosis; site and stage of disease at diagnosis; type of surgery performed; and vital status. The Medicare data include a unique Health Insurance Claim number for each beneficiary, as well as claims for all inpatient hospitalizations, outpatient hospital services, physician services, durable medical equipment, skilled nursing home care, and hospice services for beneficiaries with FFS coverage. Prescription drug information is available for beneficiaries with FFS or MA coverage who have opted to enroll in Medicare Part D. All Medicare claims include dates of service and codes for specific diagnoses, procedures, and medications. The SEER and Medicare data are linked biennially. The current version of the SEER-Medicare data includes cancer cases diagnosed from 1973-2013 and Medicare claims through 2014. For persons reported to SEER who were age 65 years or older at the time of cancer diagnosis, 94% have been linked to the Medicare enrollment file.
MDS
The MDS is a standardized, comprehensive assessment instrument that is used for all individuals who receive care in a Medicare and/or Medicaid-certified nursing home, regardless of source of payment. The MDS was implemented in 1990 in response to the Nursing Home Reform Act of 1987 and has provided the basis for care planning, payment, quality monitoring, and research in the nursing home setting. In October 2010, the Centers for Medicare and Medicaid Services implemented version 3.0 of the Minimum Data Set (MDS 3.0) in all certified nursing homes in the United States. The MDS 3.0 captures information about patients' comorbidities, physical, psychological, and psychosocial functioning in addition to any treatments (eg, hospice care, oxygen therapy, chemotherapy, dialysis) or therapies (eg, physical, occupational, speech, restorative nursing) received. MDS measures have been demonstrated to have strong validity and reliability. [9] [10] [11] [12] [13] [14] [15] Assessments are conducted by trained nursing home clinicians on all patients at admission and discharge, in addition to other time intervals (eg, quarterly, annually, and when residents experience a significant change in status). Responses to specific questions are based on input from the patient and the clinician completing the assessment. Each MDS assessment includes the Medicare beneficiary's unique identification number, an encrypted number created by Medicare to ensure the privacy of beneficiaries.
Linkage of SEER-Medicare Data to MDS
We used data from the most current version of the 
Analytic Samples and Analysis
From the population of SEER-Medicare beneficiaries with at least 1 MDS assessment over the period of 2011-2014, we developed 2 different analytic samples: (1) All SEER-Medicare patients receiving care in the nursing home, 2011-2014; and (2) All SEER-Medicare patients newly admitted to a nursing home after January 1, 2011. Patients could have multiple MDS assessments during their nursing home stay. We included MDS data from the first assessment, or "target" assessment, appearing for patients during the period 2011-2014. For the population of patients newly admitted to nursing homes, the target assessment was identified as the first full assessment during their first episode of care. MDS assessments are performed on all patients whether they have FFS or MA coverage. However, for persons included in the SEER-Medicare data, claims are only available for Medicare beneficiaries who have FFS coverage. We present findings for the subgroup of patients who had Medicare FFS coverage during the month of their target assessment in an online Appendix (Supplemental Digital Content 1, http:// links.lww.com/MLR/B531).
We summarized the characteristics of SEER-Medicare patients in nursing homes with standard descriptive measures including medians, means, SDs, frequencies, and proportions. Characteristics from the SEER-Medicare data included patient demographics, the type of cancer, and date of diagnosis. We present information from the MDS assessments of new admissions including source of admission, the presence of selected comorbid conditions, summary measures of functional and cognitive impairment, mental health, and length of stay. Functional impairment was determined from a 28-point Activities of Daily Living (ADL) scale where 0 = Total Independence and 28 = Total Dependence. 16 Cognitive impairment was derived from a Cognitive Function Scale with 4 categories ranging from cognitively intact to severely impaired. 17 Depression severity was assessed using the Patient Health Questionnaire 9-Item Depression Screener (PHQ-9 and PHQ-9-OV). 10 In addition, we present information on the number and proportion of residents with a prognosis of <6 months as assessed by a physician, and the percent of patients that ever received hospice services in the nursing home. We also calculated the time between the date of admission (from the MDS) and the date of cancer diagnosis (from the SEER-Medicare data). We present the median time and months from cancer diagnosis to the date of admission during this time period, ranging from an admission 1+ month before diagnosis to 60+ months after the cancer diagnosis.
Finally, we present information about the geographic variation in nursing home use for SEER-Medicare cancer patients. We calculated the number of nursing homes providing services to cancer patients, by state, and then estimated the mean, median, and range of SEER-Medicare cancer patients per nursing home. Data are presented separately for states in the SEER and non-SEER areas.
RESULTS
We identified 1,887,592 individuals in the SEERMedicare data who were diagnosed with cancer between 2004-2013 and were alive on January 1, 2011. Of these, we matched 16.8% (n = 318,617) SEER-Medicare patients to the 2011-2014 MDS. Of these matches, 256,947 cancer patients were newly admitted to nursing homes during this time period (Table 1) . Among new admissions, 191,465 were Medicare FFS beneficiaries (Table 2 ) and of the individuals with a nursing home stay during the time period, 223,586 were Medicare FFS beneficiaries ( Table 2 ). The cancers with highest incidence in the United States, namely breast, prostate, lung, and colorectal cancers, made up the greatest number of stays and admissions during this time period. Among SEER-Medicare patients, those with lung, pancreatic, and colon cancers were the most likely to receive nursing home care during this time period.
Among all stays and new admissions, the majority were female, white, and over the age of 80 years ( Table 2 From the MDS assessment, of those newly admitted to nursing homes, 93.2% of all patients and 92.9% of FFS patients were admitted directly from an acute care hospital [ Table 3 ; FFS numbers in online Appendix Table 3 (Supplemental Digital Content 1, http://links.lww.com/MLR/ B531)]. Almost one third of patients were diagnosed with diabetes and 16% with congestive heart failure. The majority of patients were cognitively intact (58.3%), although 39.1% reported mild to moderate cognitive impairment; 14.6% had a diagnosis of Alzheimer disease or dementia. Almost one quarter of patients exhibited mild to severe depressive symptoms. Only 8.9% of all patients had severe functional limitations, with an average ADL Scale Score of 17.2 (SD = 5). An estimated 3.3% of patients had physician documentation of a condition or chronic disease that may result in a life expectancy of <6 months and 2.8% ever received hospice services while in a nursing home. Of those newly admitted to a nursing home during this time period, 9% had lengths of stay > 90 days.
The timing from when patients were diagnosed with cancer to when they first entered the nursing home varied by cancer diagnosis (Table 4 ). For cancers with poor prognoses, such as pancreatic, lung, and ovarian cancers, over 56%, 44%, and 40%, respectively, were admitted to the nursing home within 12 months after of their diagnosis. However, for patients with cancers that have more favorable prognosis, such as prostate and breast cancer, 10% and 12% of patients, respectively, had a nursing home admission in the year following their cancer diagnosis, with the median time between diagnosis and MDS assessment being 55 and 48 months, respectively. The concentration of SEER-Medicare patients in nursing homes varied across the country (Table 5) . SEER-Medicare patients received care in ∼70% (N = 10,953) of Medicare and Medicaid-certified United States' nursing homes during this time period; 4547 facilities were located in SEER registry states and 6406 were in non-SEER registry states. The majority (95.1%) of residents received nursing home care in SEER registry states. The median number of SEER-Medicare patients per nursing home was highest in the state of New Jersey followed by Connecticut with 122 and 89 SEER-Medicare patients in a nursing home over this time period, respectively. Of facilities in non-SEER states, Nevada had the highest median number of SEER-Medicare patients per facility with 12 patients.
DISCUSSION
In this paper, we described the SEER-Medicare-MDS data that have been linked and are available to researchers. This new data linkage has the potential to advance the science of cancer health services research, especially in the area of cancer survivorship, as well as postacute, long-term, and end-of-life care. The MDS data provide rich information not available in claims or registry data such as patients' cognitive status, physical function, and mental health, as we present in this paper. Additional items available in the MDS that will be useful to cancer health services researchers include information about pain, living arrangement, continence, fall history, and nutritional status, as well as treatments (eg, oxygen therapy, chemotherapy, dialysis) and therapies (eg, physical, occupational, speech, restorative nursing) received while a nursing home resident. The addition of the MDS data to the population-based SEERMedicare cancer registry and claims opens the possibility for a wealth of policy and practice-relevant questions, particularly given that the MDS data are available for all Medicare beneficiaries, including the growing population of MA beneficiaries with cancer for whom previous researchers have had little to no information.
Previous SEER-Medicare studies have focused on treatment in acute care hospitals, but have not had available data to understand the postacute care needs of cancer patients. There is little known about the patterns of care following hospital discharge although many cancer patients, especially those of Medicare-eligible age, need continued care to recover from their cancer surgery. With the addition of the MDS data, researchers can now investigate cancer patients' transitions between settings (eg, hospital, to nursing home for postacute care, to home). For FFS patients, the linked SEER-Medicare-MDS data can provide information about acute care services that preceded a nursing home admission as well as claims for hospitalizations that may occur while the patient is in a nursing home.
The SEER-Medicare-MDS linkage allows for a more complete picture of hospice and palliative care delivered to dying cancer patients. Historically, the SEER-Medicare data have included claims for hospice services as billed by hospice providers. The addition of the MDS data allows assessment of a patient's experience in nursing home hospice care, including pain management and mental health.
Other research opportunities with these data include investigating disparities (eg, race, sex, and urban/rural location) in postacute and long-term care for cancer patients as well as quality of care for patients with cancer (eg, untreated pain, medication use, successful discharge to home, and rehospitalization). In addition, researchers can ask questions about trends There are some limitations to these data worth noting. First, patients with nursing home stays that were too short to have a full assessment completed were not represented in this paper (n = 29,123). However, SEER-Medicare-MDS users will be able to identify these patients even if the clinical assessment information is not available. Furthermore, because we relied on the first stay during this time period to identify new nursing home entrants, it is possible that many of these patients with initial short stays are admitted to the nursing home at a later date in which a full assessment is completed and information on their clinical characteristics, functional abilities, and care received is available. Second, because of the significant changes to the MDS 3.0 implemented in the last quarter of 2010, these data only currently include information from 2011-2014, whereas the SEER-Medicare data are available from 2004 to 2013. Therefore, the timelines for these 2 data sources do not currently align. As a result, the MDS data around the time of a cancer diagnosis are limited to patients who were diagnosed from 2011 forward. As more years of SEER-Medicare and MDS data become available, the overlap of cancer data and MDS data will increase, allowing for greater number of patients to assess nursing home use during the peridiagnostic period. An additional limitation of having the MDS data starting in 2011 is that some patients identified as "newly admitted" to a nursing home in 2011 could have previously received care in a nursing home before 2011.
In conclusion, these data provide detailed, valuable information not previously available for cancer patients who receive either postacute or long-term care in United States nursing homes. Information about obtaining the SEERMedicare-MDS data can be obtained from the National Cancer Institute. 18 The addition of the MDS data to SEERMedicare files offers many opportunities for exploring new issues related to cancer health services research.
